$16.95
7.35% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Structure Therapeutics Stock price

$15.79
-6.55 29.32% 1M
-26.40 62.57% 6M
-11.33 41.78% YTD
-25.11 61.39% 1Y
+0.79 5.27% 3Y
+0.79 5.27% 5Y
+0.79 5.27% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-1.52 8.78%
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Key metrics

Market capitalization $904.56m
Enterprise Value $24.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-158.35m
Free Cash Flow (TTM) Free Cash Flow $-117.99m
Cash position $883.52m
EPS (TTM) EPS $-2.32
P/E forward negative
P/S forward 19.90
EV/Sales forward 0.55
Short interest 14.57%
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Structure Therapeutics forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a Structure Therapeutics forecast:

Buy
100%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.03 3.03
219% 219%
-
-3.03 -3.03
219% 219%
-
- Selling and Administrative Expenses 43 43
41% 41%
-
- Research and Development Expense 109 109
56% 56%
-
-155 -155
53% 53%
-
- Depreciation and Amortization 3.03 3.03
219% 219%
-
EBIT (Operating Income) EBIT -158 -158
54% 54%
-
Net Profit -123 -123
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Positive
Seeking Alpha
13 days ago
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small mo...
Negative
The Motley Fool
about 2 months ago
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
Neutral
GlobeNewsWire
2 months ago
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
More Structure Therapeutics News

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 163
Founded 2019
Website www.structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today